The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study

por Sosinsky, Alexandra Z., Song, Yufei, Gunawardhana, Lhanoo, Phillips, Syd, Page, Matt
Publicado 2023

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder

por Childress, Ann C., Lloyd, Eric, Johnson, Steven A., Gunawardhana, Lhanoo, Arnold, Valerie
Publicado 2022

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

por Gunawardhana, Lhanoo, Becker, Michael A., Whelton, Andrew, Hunt, Barbara, Castillo, Majin, Saag, Kenneth
Publicado 2018

Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo‐Controlled Study

por Saag, Kenneth G., Becker, Michael A., Whelton, Andrew, Hunt, Barbara, Castillo, Majin, Kisfalvi, Krisztina, Gunawardhana, Lhanoo
Publicado 2018

Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study

por Gunawardhana, Lhanoo, McLean, Lachy, Punzi, Henry A., Hunt, Barbara, Palmer, Robert N., Whelton, Andrew, Feig, Daniel I.
Publicado 2017

Effects of Febuxostat in Early Gout: A Randomized, Double‐Blind, Placebo‐Controlled Study

por Dalbeth, Nicola, Saag, Kenneth G., Palmer, William E., Choi, Hyon K., Hunt, Barbara, MacDonald, Patricia A., Thienel, Ulrich, Gunawardhana, Lhanoo
Publicado 2017

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in...

por Saag, Kenneth G., Becker, Michael A., White, William B., Whelton, Andrew, Borer, Jeffrey S., Gorelick, Philip B., Hunt, Barbara, Castillo, Majin, Gunawardhana, Lhanoo
Publicado 2022